Eisai Inc. and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced results from presentations of new data and analyses of LENVIMA® (lenvatinib), an orally...

Salix Pharmaceuticals, a leading specialty pharmaceutical company committed to the prevention and treatment of gastrointestinal disorders, today announced the presentation of new investigational...

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that its investigational treatment solriamfetol demonstrated long-term maintenance of efficacy and a tolerable safety profile in the...

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that Xyrem® (sodium oxybate) oral solution, CIII, demonstrated long-term efficacy for up to one year in reducing cataplexy and excessive...

AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, today announced positive data from the Phase 2 CAPTIVATE (PCYC-1142) study evaluating IMBRUVICA® (ibrutinib) in combination...

Polaris Group announced results from a phase 1 clinical study, showing that Polaris lead therapeutic candidate ADI-PEG 20 in combination with FOLFOX demonstrated promising efficacy for heavily...

Salix Pharmaceuticals, Ltd. ("Salix"), one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases, will present Phase...

Astellas Pharma Inc. (TSE: 4503, President and CEO: Kenji Yasukawa, Ph.D., "Astellas") and Seattle Genetics, Inc. (Nasdaq: SGEN) today announced the presentation of updated phase 1 data of...

At the 66th ASMS Conference, Bruker announces innovative mass spectrometry products and workflows for breakthroughs in life-science research, in clinical research and large-cohort validations in...

Year after year, citations of businesses with workers who experienced accidents due to the lack of effective lockout/tagout (LOTO) programs rank among OSHA's top ten most-cited violations....